AC
GHDX

Ascend Capital’s Genomic Health, Inc. GHDX Stock Holding History

Ascend Capital’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-75,000
Closed -$1.94M – 184
2016
Q2 		$1.94M Buy
+75,000
New +$1.99M 0.13% 120

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's GHDX Position: Q3 2016 in Review

Ascend Capital sold out of Genomic Health, Inc. (GHDX) in Q3 2016, closing a stake of 75,000 shares — an estimated $1.94M sold.

Ascend Capital first reported a position in GHDX in Q2 2016 and held it in 1 quarter. The position peaked at $1.94M in Q2 2016. 134 funds tracked by Wall St. Rank hold GHDX as of Q3 2016.

  • Ascend Capital reported no remaining Genomic Health, Inc. position as of Q3 2016 after selling out during the quarter.
  • Ascend Capital sold 75,000 Genomic Health, Inc. shares in Q3 2016, an estimated $1.94M.
  • Ascend Capital first reported a position in Genomic Health, Inc. in Q2 2016 and held it in 1 quarter.
  • Ascend Capital's Genomic Health, Inc. position peaked at $1.94M in Q2 2016.
  • 134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2016.

Based on Ascend Capital's 13F filing for Q3 2016, filed 14 Nov 2016.